CVAC is now working on a 'next generation' COVID-19 vaccine candidate with GlaxoSmithKline.
And I was right, and the cynics were wrong. Here's why that matters more than ever now.
I prefer the bear put spread over the covered equity play due to the decreased risk to principal, despite the capped potential for profit.
The stock has rallied nine-fold over the last decade, while the dividend ha increased at a double-digit rate every single year for more than a decade.
I don't want to miss the next trends because I feared the anecdotal which would have been just plain wrong.
Here's the area where I would like to go long MRNA.
Leading investment advisors provide a menu of attractive QSR stocks.
It was one thing to be Melvin Capital earlier this year. It would be something else altogether not to have learned from that hard lesson.
Traders could go long JBLU at its current altitude.